Sign in

ESAB Corporation ESAB

Price 74.7 USD
as of 2026-09-05
37/100
Weak
Quality42
Growth31
Balance-sheet strength42
Valuation47
Momentum12
Income40

Composite 37/100; the shares have moved about 53% annualised. Names that move more contribute more risk for the same amount invested, and our composite reflects how strong the evidence for this one is right now.

Strongest counter-signal

Momentum ranks 12/100 — a strong mark against it.

Case for

Its least weak area is Valuation at 47.

Case against

Momentum ranks 12/100 — a strong mark against it. Growth ranks 31/100 — a moderate mark against it. Income ranks 40/100 — a slight mark against it.

What the company does ESAB Corporation designs, manufactures, and supplies consumables and equipment for metal cutting, joining, automated welding, and gas control. Its products are sold globally through independent distributors and direct sales teams across Europe, Asia Pacific, South America, and the Middle East.

Key financials ESAB’s trailing P/E is 22.34x with a forward P/E of 14.73x, EV/EBITDA at 13.21x, and a PEG of 0.28. Margins include gross 36.7%, operating 13.5%, and net 7.1%. ROE is 11.4%, ROA 5.8%, and ROCE 8.1%, with revenue growth at 9.9% but EPS down -28.9%.

Stock health Sidera’s overall score is 42.6 (Weak quality, fairly valued, weak momentum). Momentum metrics show -11.01% (3m), -27.05% (6m), and -34.07% (12m), with RSI(14) at 44.20. Profitability ratios (Piotroski 5/9, Altman Z 2.19) and leverage (Debt/Equity 0.96) reflect moderate financial risk.

Price vs fair value ESAB trades at a PREMIUM of 26.90% to our fair-value estimate of 62.61 and at a discount of 58.20% to the 12-month target of 135.40. - Analysts expect earnings growth ahead of the next release (Zacks) - Forward P/E of 14.73x is below the trailing 22.34x, suggesting valuation compression - Weak momentum scores (Momentum 19.4) and negative 12-month return (-34.07%) weigh on sentiment

Looking forward Forward earnings expectations and a discounted forward multiple may support a re-rating if execution improves. However, weak momentum and high premium to fair value cap near-term upside. Watch margin trends and capital allocation for signs of quality improvement.

sideravia.comEvery stock argues both sides.
Research, not advice · sideravia.com/conflicts — read the policy

This is not investment advice. Sideravia provides automated, data-driven analysis for information and education only. Nothing on this page is a personal recommendation or an invitation to buy or sell any security, and it does not consider your objectives or financial situation. Assessments are generated by rules applied uniformly to every covered stock — how our scores work.

Data as of 2026-09-05, compiled from third-party sources; errors and delays are possible and figures are not warranted. Investing puts your capital at risk; past performance does not predict future results. We publish our full track record, including the calls that lost, and our conflicts of interest.